Mutations of the BRAF gene in human cancer, Nature, vol.7, issue.6892, pp.949-54, 2002. ,
DOI : 10.1006/geno.2000.6354
Distinct Sets of Genetic Alterations in Melanoma, New England Journal of Medicine, vol.353, issue.20, pp.2135-2182, 2005. ,
DOI : 10.1056/NEJMoa050092
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2523, 2011. ,
DOI : 10.1056/NEJMoa1103782
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, The Lancet, vol.380, issue.9839, pp.358-65, 2012. ,
DOI : 10.1016/S0140-6736(12)60868-X
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study, The Lancet Oncology, vol.15, issue.3, pp.323-355, 2014. ,
DOI : 10.1016/S1470-2045(14)70012-9
An update on overall survival (OS) and follow-on therapies in BREAK, a phase II randomized trial:dabrafenib(D) dacarbazine (DTIC) in patients (PTS) with BRAF V600E, Ann Oncol, vol.25, issue.1, p.1092, 2015. ,
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation, Nature, vol.21, issue.7326, pp.968-72, 2010. ,
DOI : 10.1038/nature09627
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K, Cancer Cell, vol.18, issue.6, pp.683-95, 2010. ,
DOI : 10.1016/j.ccr.2010.11.023
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E), Nature, vol.11, issue.7377, pp.387-90, 2011. ,
DOI : 10.1038/nature10662
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy, Cancer Discovery, vol.4, issue.1, pp.80-93, 2014. ,
DOI : 10.1158/2159-8290.CD-13-0642
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3936420
Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma, Journal of Clinical Oncology, vol.31, issue.14, pp.1767-74, 2013. ,
DOI : 10.1200/JCO.2012.44.7888
Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study, The Lancet Oncology, vol.15, issue.9, pp.954-65, 2014. ,
DOI : 10.1016/S1470-2045(14)70301-8
-Mutated Melanoma, New England Journal of Medicine, vol.371, issue.20, pp.1867-76, 2014. ,
DOI : 10.1056/NEJMoa1408868
URL : https://hal.archives-ouvertes.fr/hal-00608409
Final Version of 2009 AJCC Melanoma Staging and Classification, Journal of Clinical Oncology, vol.27, issue.36, pp.6199-206, 2009. ,
DOI : 10.1200/JCO.2009.23.4799
mutations in patients with metastatic melanoma, Cancer, vol.18, issue.21, pp.3821-3850, 2013. ,
DOI : 10.1002/cncr.28306
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma, New England Journal of Medicine, vol.371, issue.20, pp.1877-88, 2014. ,
DOI : 10.1056/NEJMoa1406037
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial, The Lancet, vol.386, issue.9992, pp.444-51, 2015. ,
DOI : 10.1016/S0140-6736(15)60898-4
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib, New England Journal of Medicine, vol.372, issue.1, pp.30-39, 2015. ,
DOI : 10.1056/NEJMoa1412690
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-275, 2009. ,
DOI : 10.1016/j.ejca.2008.10.026
Sex Steroid Hormone Receptors in Human Thymoma, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.5, pp.2309-2326, 2003. ,
DOI : 10.1210/jc.2002-021353
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology, JNCI Journal of the National Cancer Institute, vol.85, issue.5, pp.365-76, 1993. ,
DOI : 10.1093/jnci/85.5.365
Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies, Tumori, vol.99, pp.302-307, 2013. ,
Prognostic score for patients with advanced melanoma treated with ipilimumab, European Journal of Cancer, vol.51, issue.18, pp.2785-91, 2015. ,
DOI : 10.1016/j.ejca.2015.09.007
3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma, European Journal of Cancer, vol.51, p.663, 2015. ,
DOI : 10.1016/S0959-8049(16)31820-2
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma, Cancer Immunology, Immunotherapy, vol.369, issue.2, pp.449-58, 2014. ,
DOI : 10.1007/s00262-014-1528-9
Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma, J Clin Oncol, vol.33, issue.9020, 2015. ,
Incidence, course, and management of toxicities associated with vemurafenib and cobimetinib in the coBRIM study, Society for Melanoma Research, 2014. ,
Vemurafenib and cobimetinib potently inhibit PS6 signaling in BRAFV600 mutation-positive locally advanced or metastatis melanoma from BRIM7 study ,
31 Cotellic 20 mg fi lm-coated tablets (summary of product characteristics) Welwyn Garden City, UK: Roche Registration Limited 32 Zelboraf 240 mg fi lm-coated tablets (summary of product characteristics), 2015. ,